Detection of Specific IgE Antibodies to Nafamostat Mesilate as an Indication of Possible Adverse Effects of Leukocytapheresis using Nafamostat Mesilate as Anticoagulant
: The aim was to determine whether adverse effects of leukocytapheresis (LCAP) are related to nafamostat mesilate (NM) as an anticoagulant. Anti‐NM IgE were detected in inflammatory bowel disease (IBD) patients who were administrated LCAP in our institute. Forty‐nine patients (ulcerative colitis (UC...
Gespeichert in:
| Veröffentlicht in: | Therapeutic apheresis 2004-02, Vol.8 (1), p.45-51 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 51 |
|---|---|
| container_issue | 1 |
| container_start_page | 45 |
| container_title | Therapeutic apheresis |
| container_volume | 8 |
| creator | Nagase, Kazuko Fukunaga, Ken Ohnishi, Kunio Kusaka, Takeshi Matoba, Yoshika Sawada, Koji |
| description | : The aim was to determine whether adverse effects of leukocytapheresis (LCAP) are related to nafamostat mesilate (NM) as an anticoagulant. Anti‐NM IgE were detected in inflammatory bowel disease (IBD) patients who were administrated LCAP in our institute. Forty‐nine patients (ulcerative colitis (UC)/Crohn's disease (CD): 30/19) were evaluated. Anti‐NM IgE was measured by the ELISA method. Total IgE level and eosinophil count was tested concurrently. We retrospectively checked the presence of allergic symptoms and medications used concurrently with LCAP. Anti‐NM IgE were present in six symptomatic patients (6/49; 12.2%) whose adverse effects were highly suspected to be from NM. However, 21 patients showed anti NM IgE‐negative, in spite of the fact that their adverse effects were also highly suspected to be from NM. Through the detection of anti‐NM IgE alone we could not estimate the relevance of NM as an anticoagulant to the adverse effects of LCAP. |
| doi_str_mv | 10.1111/j.1526-0968.2004.00086.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20798113</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20798113</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5236-ba1ecf1c3d65319ff95b6ca4c1fef09ef13fc680a9529d2a31286dc1b9a197333</originalsourceid><addsrcrecordid>eNqNkc1uEzEUhS0EoqXwCsgrdjP1z_xZYhPaUFKloahBLC2P5zo4nYzD2FOSN-Ix6yGhrJDwxle655x77Q8hTElK4zlfpzRnRUJEUaWMkCwlhFRFunuGTmmZZYkQVfn8qS7FCXrl_ZoQxjLOX6ITmlNWESpO0a9LCKCDdR12Bt9tQVtjNZ6tpnjSBVu7xoLHweGFMmrjfFAB34C3rQqAlceqw7OusVr9ibh13tu6BTxpHqD3gKfGxAF-7M1huHd6H9T2O_QxxOPB2271r-xxAe3UamhVF16jF0a1Ht4c7zP09eN0efEpmX--ml1M5onOGS-SWlHQhmreFDmnwhiR14VWmaYGDBFgKDe6qIgSORMNUzx-RNFoWgtFRck5P0PvDrnb3v0YwAe5sV5DG3cAN3jJSCkqSkdhdRDqPj65ByO3vd2ofi8pkSMluZYjJTlSkiMl-ZuS3EXr2-OMod5A89d4xBIF7w-Cn7aF_X8Hy-XkNhbRnhzs1gfYPdlVfy-Lkpe5_La4kl_u8g_XN8tLueCPzcazSQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20798113</pqid></control><display><type>article</type><title>Detection of Specific IgE Antibodies to Nafamostat Mesilate as an Indication of Possible Adverse Effects of Leukocytapheresis using Nafamostat Mesilate as Anticoagulant</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Nagase, Kazuko ; Fukunaga, Ken ; Ohnishi, Kunio ; Kusaka, Takeshi ; Matoba, Yoshika ; Sawada, Koji</creator><creatorcontrib>Nagase, Kazuko ; Fukunaga, Ken ; Ohnishi, Kunio ; Kusaka, Takeshi ; Matoba, Yoshika ; Sawada, Koji</creatorcontrib><description>: The aim was to determine whether adverse effects of leukocytapheresis (LCAP) are related to nafamostat mesilate (NM) as an anticoagulant. Anti‐NM IgE were detected in inflammatory bowel disease (IBD) patients who were administrated LCAP in our institute. Forty‐nine patients (ulcerative colitis (UC)/Crohn's disease (CD): 30/19) were evaluated. Anti‐NM IgE was measured by the ELISA method. Total IgE level and eosinophil count was tested concurrently. We retrospectively checked the presence of allergic symptoms and medications used concurrently with LCAP. Anti‐NM IgE were present in six symptomatic patients (6/49; 12.2%) whose adverse effects were highly suspected to be from NM. However, 21 patients showed anti NM IgE‐negative, in spite of the fact that their adverse effects were also highly suspected to be from NM. Through the detection of anti‐NM IgE alone we could not estimate the relevance of NM as an anticoagulant to the adverse effects of LCAP.</description><identifier>ISSN: 1744-9979</identifier><identifier>ISSN: 1091-6660</identifier><identifier>EISSN: 1744-9987</identifier><identifier>DOI: 10.1111/j.1526-0968.2004.00086.x</identifier><identifier>PMID: 15128019</identifier><language>eng</language><publisher>Melbourne, Australia: Blackwell Science Pty</publisher><subject>Adult ; Adverse effects ; Aged ; Anti-nafamostat mesilate IgE ; Anticoagulant ; Anticoagulants - adverse effects ; Anticoagulants - therapeutic use ; Enzyme-Linked Immunosorbent Assay ; Eosinophils - metabolism ; Female ; Guanidines - adverse effects ; Guanidines - therapeutic use ; Humans ; Immunoglobulin E - blood ; Inflammatory bowel disease ; Inflammatory Bowel Diseases - therapy ; Leukapheresis ; Leukocytapheresis ; Leukocyte Count ; Male ; Middle Aged ; Nafamostat mesilate ; Retrospective Studies</subject><ispartof>Therapeutic apheresis, 2004-02, Vol.8 (1), p.45-51</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5236-ba1ecf1c3d65319ff95b6ca4c1fef09ef13fc680a9529d2a31286dc1b9a197333</citedby><cites>FETCH-LOGICAL-c5236-ba1ecf1c3d65319ff95b6ca4c1fef09ef13fc680a9529d2a31286dc1b9a197333</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1526-0968.2004.00086.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1526-0968.2004.00086.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15128019$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nagase, Kazuko</creatorcontrib><creatorcontrib>Fukunaga, Ken</creatorcontrib><creatorcontrib>Ohnishi, Kunio</creatorcontrib><creatorcontrib>Kusaka, Takeshi</creatorcontrib><creatorcontrib>Matoba, Yoshika</creatorcontrib><creatorcontrib>Sawada, Koji</creatorcontrib><title>Detection of Specific IgE Antibodies to Nafamostat Mesilate as an Indication of Possible Adverse Effects of Leukocytapheresis using Nafamostat Mesilate as Anticoagulant</title><title>Therapeutic apheresis</title><addtitle>Ther Apher Dial</addtitle><description>: The aim was to determine whether adverse effects of leukocytapheresis (LCAP) are related to nafamostat mesilate (NM) as an anticoagulant. Anti‐NM IgE were detected in inflammatory bowel disease (IBD) patients who were administrated LCAP in our institute. Forty‐nine patients (ulcerative colitis (UC)/Crohn's disease (CD): 30/19) were evaluated. Anti‐NM IgE was measured by the ELISA method. Total IgE level and eosinophil count was tested concurrently. We retrospectively checked the presence of allergic symptoms and medications used concurrently with LCAP. Anti‐NM IgE were present in six symptomatic patients (6/49; 12.2%) whose adverse effects were highly suspected to be from NM. However, 21 patients showed anti NM IgE‐negative, in spite of the fact that their adverse effects were also highly suspected to be from NM. Through the detection of anti‐NM IgE alone we could not estimate the relevance of NM as an anticoagulant to the adverse effects of LCAP.</description><subject>Adult</subject><subject>Adverse effects</subject><subject>Aged</subject><subject>Anti-nafamostat mesilate IgE</subject><subject>Anticoagulant</subject><subject>Anticoagulants - adverse effects</subject><subject>Anticoagulants - therapeutic use</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Eosinophils - metabolism</subject><subject>Female</subject><subject>Guanidines - adverse effects</subject><subject>Guanidines - therapeutic use</subject><subject>Humans</subject><subject>Immunoglobulin E - blood</subject><subject>Inflammatory bowel disease</subject><subject>Inflammatory Bowel Diseases - therapy</subject><subject>Leukapheresis</subject><subject>Leukocytapheresis</subject><subject>Leukocyte Count</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Nafamostat mesilate</subject><subject>Retrospective Studies</subject><issn>1744-9979</issn><issn>1091-6660</issn><issn>1744-9987</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc1uEzEUhS0EoqXwCsgrdjP1z_xZYhPaUFKloahBLC2P5zo4nYzD2FOSN-Ix6yGhrJDwxle655x77Q8hTElK4zlfpzRnRUJEUaWMkCwlhFRFunuGTmmZZYkQVfn8qS7FCXrl_ZoQxjLOX6ITmlNWESpO0a9LCKCDdR12Bt9tQVtjNZ6tpnjSBVu7xoLHweGFMmrjfFAB34C3rQqAlceqw7OusVr9ibh13tu6BTxpHqD3gKfGxAF-7M1huHd6H9T2O_QxxOPB2271r-xxAe3UamhVF16jF0a1Ht4c7zP09eN0efEpmX--ml1M5onOGS-SWlHQhmreFDmnwhiR14VWmaYGDBFgKDe6qIgSORMNUzx-RNFoWgtFRck5P0PvDrnb3v0YwAe5sV5DG3cAN3jJSCkqSkdhdRDqPj65ByO3vd2ofi8pkSMluZYjJTlSkiMl-ZuS3EXr2-OMod5A89d4xBIF7w-Cn7aF_X8Hy-XkNhbRnhzs1gfYPdlVfy-Lkpe5_La4kl_u8g_XN8tLueCPzcazSQ</recordid><startdate>200402</startdate><enddate>200402</enddate><creator>Nagase, Kazuko</creator><creator>Fukunaga, Ken</creator><creator>Ohnishi, Kunio</creator><creator>Kusaka, Takeshi</creator><creator>Matoba, Yoshika</creator><creator>Sawada, Koji</creator><general>Blackwell Science Pty</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>200402</creationdate><title>Detection of Specific IgE Antibodies to Nafamostat Mesilate as an Indication of Possible Adverse Effects of Leukocytapheresis using Nafamostat Mesilate as Anticoagulant</title><author>Nagase, Kazuko ; Fukunaga, Ken ; Ohnishi, Kunio ; Kusaka, Takeshi ; Matoba, Yoshika ; Sawada, Koji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5236-ba1ecf1c3d65319ff95b6ca4c1fef09ef13fc680a9529d2a31286dc1b9a197333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adult</topic><topic>Adverse effects</topic><topic>Aged</topic><topic>Anti-nafamostat mesilate IgE</topic><topic>Anticoagulant</topic><topic>Anticoagulants - adverse effects</topic><topic>Anticoagulants - therapeutic use</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Eosinophils - metabolism</topic><topic>Female</topic><topic>Guanidines - adverse effects</topic><topic>Guanidines - therapeutic use</topic><topic>Humans</topic><topic>Immunoglobulin E - blood</topic><topic>Inflammatory bowel disease</topic><topic>Inflammatory Bowel Diseases - therapy</topic><topic>Leukapheresis</topic><topic>Leukocytapheresis</topic><topic>Leukocyte Count</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Nafamostat mesilate</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nagase, Kazuko</creatorcontrib><creatorcontrib>Fukunaga, Ken</creatorcontrib><creatorcontrib>Ohnishi, Kunio</creatorcontrib><creatorcontrib>Kusaka, Takeshi</creatorcontrib><creatorcontrib>Matoba, Yoshika</creatorcontrib><creatorcontrib>Sawada, Koji</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Therapeutic apheresis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nagase, Kazuko</au><au>Fukunaga, Ken</au><au>Ohnishi, Kunio</au><au>Kusaka, Takeshi</au><au>Matoba, Yoshika</au><au>Sawada, Koji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Detection of Specific IgE Antibodies to Nafamostat Mesilate as an Indication of Possible Adverse Effects of Leukocytapheresis using Nafamostat Mesilate as Anticoagulant</atitle><jtitle>Therapeutic apheresis</jtitle><addtitle>Ther Apher Dial</addtitle><date>2004-02</date><risdate>2004</risdate><volume>8</volume><issue>1</issue><spage>45</spage><epage>51</epage><pages>45-51</pages><issn>1744-9979</issn><issn>1091-6660</issn><eissn>1744-9987</eissn><abstract>: The aim was to determine whether adverse effects of leukocytapheresis (LCAP) are related to nafamostat mesilate (NM) as an anticoagulant. Anti‐NM IgE were detected in inflammatory bowel disease (IBD) patients who were administrated LCAP in our institute. Forty‐nine patients (ulcerative colitis (UC)/Crohn's disease (CD): 30/19) were evaluated. Anti‐NM IgE was measured by the ELISA method. Total IgE level and eosinophil count was tested concurrently. We retrospectively checked the presence of allergic symptoms and medications used concurrently with LCAP. Anti‐NM IgE were present in six symptomatic patients (6/49; 12.2%) whose adverse effects were highly suspected to be from NM. However, 21 patients showed anti NM IgE‐negative, in spite of the fact that their adverse effects were also highly suspected to be from NM. Through the detection of anti‐NM IgE alone we could not estimate the relevance of NM as an anticoagulant to the adverse effects of LCAP.</abstract><cop>Melbourne, Australia</cop><pub>Blackwell Science Pty</pub><pmid>15128019</pmid><doi>10.1111/j.1526-0968.2004.00086.x</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1744-9979 |
| ispartof | Therapeutic apheresis, 2004-02, Vol.8 (1), p.45-51 |
| issn | 1744-9979 1091-6660 1744-9987 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_20798113 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Adverse effects Aged Anti-nafamostat mesilate IgE Anticoagulant Anticoagulants - adverse effects Anticoagulants - therapeutic use Enzyme-Linked Immunosorbent Assay Eosinophils - metabolism Female Guanidines - adverse effects Guanidines - therapeutic use Humans Immunoglobulin E - blood Inflammatory bowel disease Inflammatory Bowel Diseases - therapy Leukapheresis Leukocytapheresis Leukocyte Count Male Middle Aged Nafamostat mesilate Retrospective Studies |
| title | Detection of Specific IgE Antibodies to Nafamostat Mesilate as an Indication of Possible Adverse Effects of Leukocytapheresis using Nafamostat Mesilate as Anticoagulant |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T08%3A23%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Detection%20of%20Specific%20IgE%20Antibodies%20to%20Nafamostat%20Mesilate%20as%20an%20Indication%20of%20Possible%20Adverse%20Effects%20of%20Leukocytapheresis%20using%20Nafamostat%20Mesilate%20as%20Anticoagulant&rft.jtitle=Therapeutic%20apheresis&rft.au=Nagase,%20Kazuko&rft.date=2004-02&rft.volume=8&rft.issue=1&rft.spage=45&rft.epage=51&rft.pages=45-51&rft.issn=1744-9979&rft.eissn=1744-9987&rft_id=info:doi/10.1111/j.1526-0968.2004.00086.x&rft_dat=%3Cproquest_cross%3E20798113%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20798113&rft_id=info:pmid/15128019&rfr_iscdi=true |